GLEN ALLEN, Va., July 7, 2022 /CNW/ -- Glaucoma, one of the world's leading causes of irreversible blindness, is expected to affect an estimated 120 million by 2040, globally. Treatment options for ...
Remidio Innovative Solutions announced the publication of a landmark independent evaluation of regulatory-approved diabetic retinopathy (DR) artificial intelligence algorithms in The Lancet Digital ...
Diagnosing eye diseases requires bulky machines and specialist clinics, which are often concentrated in large cities. But for millions living in smaller towns and rural regions, access to timely eye ...
GLEN ALLEN, Va., May 7, 2024 /PRNewswire/ -- Remidio Inc., a health technology innovator developing cutting-edge technology to combat global blindness from Diabetic Retinopathy, Glaucoma, AMD, & ...
GLEN ALLEN, Va., Sept. 30, 2022 /CNW/ -- Remidio Inc will launch a lightweight, handheld portable auto refractometer, Instaref R20, for refractive error measurements ...
Remidio Innovative Solutions, India's leading AI-powered medical imaging company, will showcase its breakthrough eye care technology at the India AI Impact Summit 2026, demonstrating how Indian ...
Hosted on MSN
India’s Remidio invests in UK’s Occuity to enhance non-invasive global disease screening
New Delhi: In a move set to redefine non-invasive disease detection, Remidio, a global leader in AI-powered ophthalmic solutions, has invested in Occuity, a UK-based developer of handheld, optical ...
World's first Smartphone based offline AI expands geographical scope to deliver convenience and increase access to DR screening. BANGALORE, India, Feb. 23, 2023 /PRNewswire/ -- Remidio has received CE ...
BENGALURU: Anand Sivaraman met Anand Vinekar in a train coming from Coimbatore to Bengaluru, where they both lived. Sivaraman, a PhD in chemical engineering, was working with biotech firm Reametrix.
Bengaluru: Medtech startup Remidio has unveiled Neubo 130, an AI-powered retinal imaging device designed to diagnose neonatal retinal conditions such as Retinopathy of Prematurity (ROP). “The launch ...
Bangalore (Karnataka) [India], February 23 (ANI/PRNewswire): Remidio has received CE mark approval for its Medios AI, to detect Referable DR. This approval closely follows the nod the AI received from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results